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Abstract
Background: Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant
brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been
associated with increased survival and resistance to therapy. The aim of this study is to investigate the effects of
AKT inhibition in combination with the current standard of care which consists of irradiation and temozolomide
(TMZ) on human malignant glioma cells growing adherent and as multicellular spheroids in vitro.
Methods: The effects of the allosteric inhibitor MK2206 combined with irradiation and TMZ were assessed on
glioma cells growing adherent and as multicellular 3D spheroids. The interaction was studied on proliferation,
clonogenic cell survival, cell invasion, −migration and on expression of key proteins in the PI3K-AKT pathway by
western blot.
Results: A differential effect was found at low- (1 μM) and high dose (10 μM) MK2206. At 1 μM, the inhibitor
reduced phosphorylation of Thr308 and Ser473 residues of AKT in both adherent cells and spheroids. Low dose
MK2206 delayed spheroid growth and sensitized spheroids to both irradiation and TMZ in a synergistic way
(Combination index <0.35). In contrast, neither low nor high dose MK2206 did enhance therapy sensitivity in
adherent growing cells. Effective inhibition of invasion and migration was observed only at higher doses of
MK2206 (>5 μM).
Conclusions: The data show that a 3D spheroid model show different sensitivity to irradiation when combined
with AKT inhibition. Thereby we show that MK2206 has potential synergistic efficacy to the current standard of care
for glioma patients.
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Background
Glioblastoma multiforme (GBM) is the most common
and aggressive primary brain tumor in adults, with an
overall incidence rate of approximately 3 per 100,000
persons per year [1]. The unique characteristics of GBM,
such as high mitotic capacity, microvascular prolifera-
tion, pseudopallisading necrosis and infiltrative growth,
confer a poor prognosis, with a median overall survival
of approximately 15 months after diagnosis [2]. Postop-
erative radiotherapy (RT) with concomitant temozolo-
mide (TMZ) has become the standard procedure in the
treatment of patients with newly diagnosed GBM, based
on the results of a large European-Canadian phase III
trial [3]. Despite these encouraging results, the majority
of patients still succumb from locally recurrent disease,
which is due to the diffuse infiltrative growth character-
istics of this tumor type and high level of resistance to
radiotherapy and chemotherapy [4]. The treatment
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response and prognosis are related to several (epi)gen-
etic characteristics of glioma like methylation status of
O6-methylguanine–DNA methyltransferase (MGMT)
and genetic events in GBM core pathways including the
phosphatidylinositide 3-kinase (PI3K) pathway [5]. PI3K
is a central upstream node related to cell survival and
cell proliferation [6]. Its primary downstream effector
protein AKT plays a pivotal role in the pathway activa-
tion via phosphorylation of AKT on two critical residues,
Thr308 (through PI3K) and Ser473 (mediated predomin-
antly via mTORC2) [6, 7]. AKT exists in three isoforms,
AKT1, −2 and −3, of which AKT2 and −3 are found to
be important in glioma cells [7, 8]. Experimental data has
indicated that phosphorylated AKT is required for proper
DNA-damage response (DDR) during Non-Homologous
end-joining (NHEJ) by binding to DNA-PKcs and promot-
ing its auto-phosphorylation [9, 10]. Pharmacological in-
hibition of AKT has therefore also been found to sensitize
cancer cells to DNA damaging agents and radiotherapy
[11, 12]. In recent years many specific PI3K/AKT/mTOR
pathway targeted agents have become available for pre-
clinical studies and clinical evaluation [13]. MK2206 is an
oral allosteric AKT inhibitor which can inhibit all isoforms
of AKT [14]. Early clinical feasibility studies already dem-
onstrated that MK2206 monotherapy is well tolerated in
patients [15]. Emerging data show MK2206 to enhance
the activity of chemotherapeutic agents in various types
of cancers both pre-clinical [14, 16–21] and in patients
[15, 22]. Data on MK2206 additional to the current
standard GBM therapy are however not available. In
the present study, we investigated the effect of MK2206
alone and its ability to synergize with radiation and
TMZ to inhibit glioma growth, invasion and migration
using monolayer human glioma cells and multicellular
glioma spheroids.
Methods
Monolayer and spheroid/organoid cell culture
Experiments were performed using the established gli-
oma cell lines U87MG (ATCC-HTB-14) and U251 (cell
line was kindly provided by Dr. C.H. Langevel, Dept.
Neurology, VU University Medical Center, Amsterdam,
The Netherlands) and on two primary cell lines VU28
and VU122 (derived directly from surgical specimens
from the VU University Medical Center). Cells were
cultured at 37 °C in Dulbecco’s modified Eagle’s medium
(D-MEM; Gibco BRL, UK) containing 10% fetal calf
serum, 100 IU ml – 1 penicillin and 100 IU ml – 1 strepto-
mycin, in at 5% CO2-humidified atmosphere. The AKT-
inhibitor MK-2206 (Selleck Chemicals®, Houston, Texas,
USA) was dissolved to a 10 mM stock solution in DMSO
and stored at −20 °C. The alkylating agent temozolomide
(Schering-Plough®, Utrecht, The Netherlands) was freshly
dissolved at 100 mM in DMSO before each treatment.
Cells and spheroids were irradiated at room temperature
radiation from a Cobalt-60 source at a dose rate of
516 Gy/h (Gammacell 220®; Atomic Energy of Canada,
Mississauga, Ontario, Canada).
Cell proliferation
U87MG Cells were plated at a density of 2000 cells/well
in a 96-well plate 24 h prior to drug treatment. Subse-
quently, cells were exposed to a serial dilution of MK2206
for 72 h in sextuple. Cell viability was determined using
Cell-titer Glo 3D (Promega), which dissociates the spher-
oids. Relative light units (RLU) were measured using the
BioTek Synergy HT Microplate Reader RLUs were nor-
malized against the untreated controls.
Western blot
Expression of total AKT (Cell Signaling #9272, Boston,
USA, 60 kDa), phospho-AKT Ser473 (Cell Signaling
#9271, 60 kDa), phospho-AKT Thr308 (Cell Signaling
#9275, 60 kDa), phospho-H2A.X (#9718) with loading
control total-S6 (#2217) proteins were evaluated by
western blot. Cells were either treated with 1 μM MK-
2206 1 h before being irradiated, and collected at
indicated time points for analysis.
Migration assay
Cells were plated at high density of 30.000 cells/well in 96-
wells plates. A day later wells were uniformly scratched
using a guided 96-well pin tool (Peira, Turnhout, Belgium)
to create wounds of approximately 300 μm wide. Wells
were washed with PBS and growth medium was added with
MK2206. Images were automatically captured on a Leica
DMI3000 microscope (Leica, Rijswijk, The Netherlands)
using Universal Grab 6.3 software (DCILabs, Keerbergen,
Belgium). Scratch sizes were determined using Scratch
Assay 6.2 (DCILabs), and absolute wound closure (μm2)
was expressed as a percentage of control wells.
Invasion assay
Cellular invasion was evaluated using Boyden chamber
assay. In short, 2 × 105 cells were seeded into each insert
of a 24-well plate (Falcon #353504, Fisher Scientific, USA)
containing serum-free medium in the upper compartment
and complete medium in the lower compartment, sepa-
rated by a matrigel (10%) membrane in D-MEM. MK-
2206 (1–10 μM) was added to both compartments. After
16 h of cell seeding the invasive capacity was assessed
using a fluorescent microscope to count the number of
cells that crossed the membrane. Fluorescence was
achieved with addition of 5 μM Calcein-AM to the lower
compartment in the last half hour of the experiment. For
the combination with irradiation, exponential growing
cells were exposed to 1 μM of MK-2206 for 1 h or 24 h,
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followed by 4 Gy irradiation and incubation at 37 °C for
one hour and then transferred to inserts.
Spheroid growth and migration
U87MG tumor spheroids were prepared from monolayer
cells which were trypsinised and seeded at a density of
5 × 106 cells/well in 6-well ultra-low attachment plate
(Corning #3471, Boston, USA) containing complete
DMEM. After 2 days, round spheroids were formed and
those with 150–250 μm diameter were collected with a
micropipette in an inverted microscope, transferred and
cultured individually again with complete DMEM in 24-
well ultra-low attachment plates (Corning #3473) for
analysis for spheroid growth. For migration analysis
these spheroids were transferred to regular adhesive 24-
well culture plates. The size of the spheroids was mea-
sured every 3-days over a 15-day period. A SONY DSC-
HX1 camera was attached to the microscope and the
pictures were always taken with the same resolution and
configuration: 2048x1536px, horizontal and vertical reso-
lution of 72 dpi, Bit depth 24, Exposure time 1/30 s, Focal
length 5 mm. The software IMAGE-J was used for the
measurement of the diameters used for the calculations of
area and volume.
Synergy calculation and statistics
Statistical analysis was done using one-way ANOVA to
compare different groups. Two-way repeated measures
ANOVA was used for the experiments with several time
points. Bonferroni post hoc test was utilized to compare
differences between groups. The value of p was adjusted
to the number of groups. Differences between two sets of
data were considered statistically significant at p < 0.05
(95% CI). The combination index (CI) for n amount of
treatments that were combined, was calculated using a
adapted formula from Chou and Talalay [23, 24] which
was used on normalized growth data, where v is cell
viability in %.
CI ndrugs½  ¼
P
1




MK2206 does not lead to temozolomide/radiation
sensitization in glioma monolayer cultures.
We investigated the efficacy of MK2206 at attenuating
U87 glioma cell proliferation and found it to be effective
at 1 μM and higher (Fig. 1a). Protein analysis showed
complete AKT dephosphorylation at 1 μM (Fig. 1c). In
the combination of MK2206 with 4 Gy irradiation or
5 μM TMZ no synergistic interaction was found.
Synergy calculations show a combination index (CI) > 1.2,
indicating a slight antagonism (Fig. 1a). Next we tested
the combination with irradiation on clonogenic cell
survival using U251 glioma cells. None of the different
MK2206 treatment schedules showed a reduction in
clonogenic survival (Fig. 1b). In line with these findings,
the expression of γH2A.X phosphorylation was not in-
creased at 24 h after 4 Gy irradiation in cells treated
with MK2206 (Fig. 1c). The data show that in monolayer
growing cell cultures MK2206 was not able to induce
sensitization to DNA damaging therapies and actually
showed antagonistic tendencies.
Low dose MK2206 sensitizes long-term U87 multicellular
spheroid cultures to irradiation and temozolomide
To further study the ability of MK2206 to sensitize gli-
oma cells, we used the capability of U87 to easily form
spheroids in low-attachment plates [25]. The growth of
spheroids was inhibited after single exposure to 1 μM
MK2206 and their growth was completely abrogated at
10 μM (Fig. 2a). Next, we treated the spheroids with
fractionated irradiation in the presence of 5 μM TMZ
and/or 1 μM MK2206. Spheroids were irradiated 3 days
after start of MK2206 treatment, and TMZ was given
1 h prior to irradiation (Fig. 2b). MK2206 sensitized U87
spheroids to radiation with the lowest CI at 0.33 and
0.42 for TMZ. Furthermore, combining all three treat-
ment modalities resulted in a strong synergy (CI > 0.33,
Fig. 2c & d) which is dependent on MK, since TMZ and
RT do not show any synergy (Fig. 2c). Spheroids showed
complete pAKT inhibition and increased γH2A.X expres-
sion after irradiation combined with MK2206 (Fig. 2e).
The data show that low-dose MK2206 can sensitize
glioma spheroids to both irradiation and TMZ.
High dose MK2206 inhibits glioma migration and
invasion.
An important aspect of glioma therapy resistance is the
ability for the cells to invade and migrate throughout
the brain. Therefore, we investigated the effect of AKT
inhibition on the mobility of glioma cells on the estab-
lished cell lines U87 and U251 and on the primary cell
lines VU28 and VU122. In Fig. 3a the invasive capabil-
ities of each cell line were quantified in the presence of
increasing doses of MK2206. U251 and VU122 showed
a decrease in invasion at a relatively high dose of 5 μM
with a further decrease at 10 μM (p < 0.01). The inva-
sion of VU28 was modestly attenuated at the low dose
of 1 μM. Higher doses did not decrease the invasion
further. Interestingly no inhibition of invasion was
observed in U87 cells. Combining MK2206 (1 μM &
10 μM) with irradiation yielded an additive interaction
for invasion inhibition for all cell lines (CI > 0.8)
(Additional file 1: Figure S1A). Wound healing experi-
ments were performed to assess migration inhibition,
using 1 μM and 10 μM MK2206 at multiple time-
points up to 8 h after start treatment (Additional file 1:
Figure S1B). All cells showed a modest yet significant
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inhibition of migration at 10 μM (Fig. 3b). VU28 was
the only cell line to have inhibition of migration at a
low dose of 1 μM. Furthermore, we set up a spheroid
outgrowth assay to study the effect of (low dose) AKT
inhibition combined with irradiation on a longer time-
scale of 4 days (Additional file 1: Figure S1B). Figure 3c
shows that the VU28 cell line is the only cell line in
which both radiation and MK alone significantly re-
duced migration and when combined leads to a mild
synergistic interaction (CI = 0.79). These results show
that AKT inhibition and irradiation do not preferen-
tially synergize in glioma mobility inhibition. However,
strong attenuation of the AKT pathway does lead to a
decrease in invasion and a mild decrease in migration.
Discussion
In the present study, we investigated the effect of AKT in-
hibition by MK2206 on adherent growing human glioma
cells and on multicellular spheroids. The most important
finding is that low dose MK2206 is able to synergistically
sensitize glioma spheroids to the current standard treat-
ment modalities in GBM therapy, i.e. irradiation and TMZ.
This is in contrast to adherent growing which showed at
best modest additivity for the combinatorial treatments.
This has not described earlier in the context of radiosensiti-
zation since the golden standard for radiosensitization has
always been monolayer clonogenic assays. Hence, studies
for evaluation of radiosensitizing agents should take in to




Fig. 1 MK2206 does not lead to temozolomide/radiation sensitization in glioma monolayer cultures. a U87MG cells were treated for 72 h with
MK2206 at indicated concentrations and treated with 5 μM TMZ or 4 Gy irradiation or the combination of both. The combination index of the
triple combination was calculated at each time point. A CI < 0.8 indicates synergy, 0.8 < > 1.2 additive, > 1.2 antagonism. Data points represent
means, ±SD (n = 3). b U251 cells were treated with 1uM MK2206 and or 4 Gy irradiation in different schedules. Top: MK was given 24 h before
(Pre-RT) irradiation and plated for colony formation; Middle: cells were treated with MK and immediately irradiated (Post-RT), cells were plated
24 h later for colony formation; Bottom: cells were treated with MK 24 h before irradiation and cells were plated for colony formation in the
presence of 1 μM MK2206. Columns represent means, ±SD (n = 2). c U87MG cells were treated with 1 μM MK and/or with 4 Gy irradiation and
lysed at indicated time points
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monolayer cultures. Cells growing in multicellular organoid
structures more faithfully resemble the context of real life
tumors. Cells in this context deal with complex interactions
due to heterotypic cell-to-cell contact, signaling, extracellu-
lar matrix deposition and intracellular structure. This micro
milieu results in gradients of oxygen, nutrients and biomol-
ecules can result in hypoxia/oxidative stress [26, 27], which
has been shown to culminate to an increase of the autopha-
gic flux near the core of spheroids [28]. Cheng and col-
leagues have previously shown that the treatment of glioma
cells with MK2206 preferentially leads to an increased
autophagic flux and that this could be increased synergistic-
ally with gefitinib leading to autophagic cell death [29, 30].
In our study RT and TMZ were used to induce genotoxic
stress (DNA-damage) which is a well-known inducer of
autophagy [31, 32]. We therefore hypothesize that AKT
inhibition together with RT/TMZ in spheroids tips the au-
tophagic equilibrium towards autophagic cell death which
cannot be achieved in adherent cells. The presence of these
mechanisms and the concomitant different phenotype
makes spheroids a preferred model over adherent mono-
layer growing cells for studying radiosensitizing potential of
targeted agents [33]. Recently, a study has shown similar re-
sults where the authors show that AKT inhibition does not
radiosensitize U87 monolayer cells but does sensitize pri-






Fig. 2 Low dose MK2206 sensitizes long-term U87MG multi-cellular spheroid cultures to irradiation and temozolomide. a U87 multicellular spheroids
were treated for 15 days with 1 μM or 10 μM MK2206. Data points represent means, ±SD (n = 8 spheroids). b-c U87 spheroids were treated for 15 days
with 1 μM MK2206 together with fractions of 5 μM TMZ or 2 Gy irradiation. Points are means, ±SD (n = 8 spheroids). d Combination index for all
combinations of MK/TMZ/RT for each time point. CI < 1 indicates synergy, CI > 1 indicates antagonism. e U87 spheroids were treated with 1 μM MK
and/or with 4 Gy irradiation and lysed at indicated time points
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cells grown as spheroids have been shown to have elevated
levels of the stem cell marker CD133 [35], indicating an-
other mechanism of how the structural organization of cells
influence internal signaling and drug response.
The ability of glioma cells to invade into the brain and
migrate to different regions of the brain is one of the most
important physical means of therapy resistance. AKT is
thought to stimulate cell migration through signaling routes
[36]. Cellular invasiveness can be inhibited by irradiation,
which has been reported before [37]. However, our data
shows a modest attenuation of glioma cell mobility through
AKT inhibition and shows synergy in only one of the four
cell lines tested (Figure 3). Nevertheless, this modest inhib-
ition together with the synergistic effect the combination
therapy shows on growth inhibition warrant further investi-
gation in an orthotopic in vivo glioma model. Cheng and
colleagues have shown MK2206 alone to have inhibitory
effects on in vivo glioma growth [30].
Conclusions
Taken together, low dose MK2206 enhanced the effect of
radiotherapy and TMZ on brain tumor spheroids in vitro
which was not seen in adherent growing cell lines. Fur-
thermore, High dose MK2206 inhibited migration and in-
vasion of glioma cells and also synergized with irradiation
in a primary GBM line. Our findings indicate the AKT
pathway to be a promising target to be combined with the
current standard of care for GBM therapy.
Additional file
Additional file 1: Figure S1. A) Number of cells invaded through
matrigel after 16 h in the presence of 4 Gy combined with 1 μM (Left) or
10 μM (Right) MK2206. Error bars represent SD over 3 replicates, * = p < 0.05.
B) U87 cells untreated. Migration of U87 cells into wound up to 8 h (Left).
Migration of U87 cells out of attached spheroids up to 4 days after spheroid




Fig. 3 High dose MK2206 inhibits glioma migration and invasion. a Number of cells invaded through matrigel after 16 h in the presence of 1 μM,
5 μM, or 10 μM MK2206. Columns represent means, ±SD (n = 3), * = p < 0.05. b Percentage of scratch area remaining compared to 0 h. Columns
represent means, ±SD (n = 10 replicates), * = p < 0.05. c Area of spheroid outgrowth. Spheroids were treated with 1 μM MK and 4 Gy irradiation
and plated in regular culture plates. Data points represent means, ±SD, (n = 8 replicates), * = p < 0.05
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